Through co-targeting the androgen receptor (AR) signaling, Diptoindonesin G robustly improved the efficacy of HSP90 inhibitors and enzalutamide in both human prostate cancer cells and in vivo xenograft mouse model.
[Prostate]
Sorry, but the selected Zotpress account can't be found.